Disposition of 3500 shares by Palczuk Linda of Avadel Pharmaceuticals subject to Rule 16b-3

AVDL Stock  USD 10.54  0.07  0.66%   
About 58% of Avadel Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Avadel Pharmaceuticals PLC stock suggests that many investors are alarmed at this time. Avadel Pharmaceuticals' investing sentiment shows overall attitude of investors towards Avadel Pharmaceuticals PLC.
  
Filed transaction by Avadel Pharmaceuticals PLC Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Avadel insider trading alert for disposition of ordinary shares by Palczuk Linda, Director, on 24th of December 2024. This event was filed by Avadel Pharmaceuticals PLC with SEC on 2024-12-24. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Avadel Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Avadel Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Avadel Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Avadel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Avadel Pharmaceuticals Fundamental Analysis

We analyze Avadel Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avadel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avadel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Avadel Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Avadel Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Avadel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Avadel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Avadel Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Avadel Pharmaceuticals Related Equities

NBIXNeurocrine Biosciences   0.29   
0%
6.0%
DVAXDynavax Technologies   0.23   
5.0%
0%
AMRXAmneal Pharmaceuticals,   0.38   
8.0%
0%
EVOKEvoke Pharma   0.61   
13.0%
0%
ALKSAlkermes Plc   0.87   
18.0%
0%
ASRTAssertio Therapeutics   1.11   
24.0%
0%
ITCIIntracellular   1.34   
29.0%
0%
ANIPANI Pharmaceuticals   1.96   
42.0%
0%
LFCRLifecore Biomedical   2.80   
61.0%
0%
IRWDIronwood Pharmaceuticals   3.05   
66.0%
0%
AQSTAquestive Therapeutics   3.83   
83.0%
0%
DERMJourney Medical   4.58   
100.0%
0%
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
1.036
Quarterly Revenue Growth
26.743
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.